Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy

Yu Cheng Su, Pierre Alain Burnouf, Kuo Hsiang Chuang, Bing Mae Chen, Tian Lu Cheng, Steve R. Roffler

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) lacks effective treatment options due to the absence of traditional therapeutic targets. The epidermal growth factor receptor (EGFR) has emerged as a promising target for TNBC therapy because it is overexpressed in about 50% of TNBC patients. Here we describe a PEG engager that simultaneously binds polyethylene glycol and EGFR to deliver PEGylated nanomedicines to EGFR + TNBC. The PEG engager displays conditional internalization by remaining on the surface of TNBC cells until contact with PEGylated nanocarriers triggers rapid engulfment of nanocargos. PEG engager enhances the anti-proliferative activity of PEG-liposomal doxorubicin to EGFR + TNBC cells by up to 100-fold with potency dependent on EGFR expression levels. The PEG engager significantly increases retention of fluorescent PEG probes and enhances the antitumour activity of PEGylated liposomal doxorubicin in human TNBC xenografts. PEG engagers with specificity for EGFR are promising for improved treatment of EGFR + TNBC patients.

Original languageEnglish
Article number15507
JournalNature Communications
Volume8
DOIs
Publication statusPublished - Jun 8 2017

Fingerprint

Triple Negative Breast Neoplasms
Nanomedicine
Medical nanotechnology
Epidermal Growth Factor Receptor
breast
Polyethylene glycols
therapy
cancer
Therapeutics
Heterografts
cells
Fluorescent Dyes
glycols
polyethylenes
actuators
probes

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. / Su, Yu Cheng; Burnouf, Pierre Alain; Chuang, Kuo Hsiang; Chen, Bing Mae; Cheng, Tian Lu; Roffler, Steve R.

In: Nature Communications, Vol. 8, 15507, 08.06.2017.

Research output: Contribution to journalArticle

Su, Yu Cheng ; Burnouf, Pierre Alain ; Chuang, Kuo Hsiang ; Chen, Bing Mae ; Cheng, Tian Lu ; Roffler, Steve R. / Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. In: Nature Communications. 2017 ; Vol. 8.
@article{d402823dfd4a422ea5b6e56f7fc301a7,
title = "Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy",
abstract = "Triple-negative breast cancer (TNBC) lacks effective treatment options due to the absence of traditional therapeutic targets. The epidermal growth factor receptor (EGFR) has emerged as a promising target for TNBC therapy because it is overexpressed in about 50{\%} of TNBC patients. Here we describe a PEG engager that simultaneously binds polyethylene glycol and EGFR to deliver PEGylated nanomedicines to EGFR + TNBC. The PEG engager displays conditional internalization by remaining on the surface of TNBC cells until contact with PEGylated nanocarriers triggers rapid engulfment of nanocargos. PEG engager enhances the anti-proliferative activity of PEG-liposomal doxorubicin to EGFR + TNBC cells by up to 100-fold with potency dependent on EGFR expression levels. The PEG engager significantly increases retention of fluorescent PEG probes and enhances the antitumour activity of PEGylated liposomal doxorubicin in human TNBC xenografts. PEG engagers with specificity for EGFR are promising for improved treatment of EGFR + TNBC patients.",
author = "Su, {Yu Cheng} and Burnouf, {Pierre Alain} and Chuang, {Kuo Hsiang} and Chen, {Bing Mae} and Cheng, {Tian Lu} and Roffler, {Steve R.}",
year = "2017",
month = "6",
day = "8",
doi = "10.1038/ncomms15507",
language = "English",
volume = "8",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy

AU - Su, Yu Cheng

AU - Burnouf, Pierre Alain

AU - Chuang, Kuo Hsiang

AU - Chen, Bing Mae

AU - Cheng, Tian Lu

AU - Roffler, Steve R.

PY - 2017/6/8

Y1 - 2017/6/8

N2 - Triple-negative breast cancer (TNBC) lacks effective treatment options due to the absence of traditional therapeutic targets. The epidermal growth factor receptor (EGFR) has emerged as a promising target for TNBC therapy because it is overexpressed in about 50% of TNBC patients. Here we describe a PEG engager that simultaneously binds polyethylene glycol and EGFR to deliver PEGylated nanomedicines to EGFR + TNBC. The PEG engager displays conditional internalization by remaining on the surface of TNBC cells until contact with PEGylated nanocarriers triggers rapid engulfment of nanocargos. PEG engager enhances the anti-proliferative activity of PEG-liposomal doxorubicin to EGFR + TNBC cells by up to 100-fold with potency dependent on EGFR expression levels. The PEG engager significantly increases retention of fluorescent PEG probes and enhances the antitumour activity of PEGylated liposomal doxorubicin in human TNBC xenografts. PEG engagers with specificity for EGFR are promising for improved treatment of EGFR + TNBC patients.

AB - Triple-negative breast cancer (TNBC) lacks effective treatment options due to the absence of traditional therapeutic targets. The epidermal growth factor receptor (EGFR) has emerged as a promising target for TNBC therapy because it is overexpressed in about 50% of TNBC patients. Here we describe a PEG engager that simultaneously binds polyethylene glycol and EGFR to deliver PEGylated nanomedicines to EGFR + TNBC. The PEG engager displays conditional internalization by remaining on the surface of TNBC cells until contact with PEGylated nanocarriers triggers rapid engulfment of nanocargos. PEG engager enhances the anti-proliferative activity of PEG-liposomal doxorubicin to EGFR + TNBC cells by up to 100-fold with potency dependent on EGFR expression levels. The PEG engager significantly increases retention of fluorescent PEG probes and enhances the antitumour activity of PEGylated liposomal doxorubicin in human TNBC xenografts. PEG engagers with specificity for EGFR are promising for improved treatment of EGFR + TNBC patients.

UR - http://www.scopus.com/inward/record.url?scp=85020671302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020671302&partnerID=8YFLogxK

U2 - 10.1038/ncomms15507

DO - 10.1038/ncomms15507

M3 - Article

AN - SCOPUS:85020671302

VL - 8

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 15507

ER -